Signadori Bio
French tech company | Builders Republic
About
Preclinical-stage biopharmaceutical company developing a next-generation immunotherapy that reprograms the body's own immune cells to attack solid tumors, built on a proprietary platform spun out of leading oncology center Institut Gustave Roussy.
Key facts
- Status
- Active
- Sectors
- Healthcare & Life Sciences
- Latest stage
- Seed
- Founded
- 2025
- City
- PARIS
- Region
- IDF
- Tracked rounds
- 1
- Amount raised
- 11 M€ raised since 2020
Funding rounds
- Seed — 2026